CMS

2 clinical trials · Condition

Record	Firm	Date
A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) (NCT07746089)	argenx	2026-09-01
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) (NCT06436742)	argenx	2024-09-24

Every clearance here is in the API, with alerts when new ones post.